Clinical determinants of fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)iodine whole body scans after (131)iodine therapy

Shamim SE 1 , Nang LB 2 , Shuaib IL 3 , Muhamad NA 4

Affiliations 

  • 1 Department of Nuclear Medicine, Radiotherapy and Oncology, Hospital Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia ; Advanced Medical and Dental Institute, Universiti Sains Malaysia, No 1-8, Persiaran Seksyen 4/1, Bandar Putra Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
  • 2 Department of Nuclear Medicine, Hospital Kuala Lumpur, Jalan Pahang, 50586 Kuala Lumpur, Malaysia ; Department of Nuclear Medicine, Hospital Putrajaya, Jalan P9, Presint 7, 62250 Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia
  • 3 Advanced Medical and Dental Institute, Universiti Sains Malaysia, No 1-8, Persiaran Seksyen 4/1, Bandar Putra Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
  • 4 Institute for Medical Research, Jalan Pahang, 50586 Kuala Lumpur, Malaysia
Malays J Med Sci, 2014 May;21(3):38-46.
PMID: 25246834

Abstract

A cross-sectional prospective study has been conducted on differentiated thyroid cancer (DTC) patients using negative (131)Iodine ((131)I) whole body scans and elevated thyroglobulin (Tg) levels. The main objective of this research was to determine the prevalence of the conversion of differentiated to dedifferentiated thyroid cancer patients during follow up at the Hospital Kuala Lumpur. It has been demonstrated that fluorodeoxyglucose (FDG) uptake is inversely proportional to the iodine concentration and to differentiation of the cells.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications